Table 4

Logistic regression analysis of rs729749 in cases stratified for autoantibody status
Status
 Subgroup
 Genotype CT versus CC
 Genotype TT versus CC




OR
 95% CI
 P
 OR
 95% CI
 P
All
 All
 0.80
 0.66 to 0.97
 0.02
 1.04
 0.67 to 1.62
 0.86

Women
 0.94
 0.75 to 1.17
 0.56
 1.01
 0.60 to 1.71
 0.97

Men
 0.50
 0.35 to 0.73
 0.0002
 1.20
 0.52 to 2.81
 0.67
RF positive
 All
 0.85
 0.69 to 1.04
 0.12
 0.92
 0.56 to 1.53
 0.76

Women
 0.96
 0.75 to 1.23
 0.74
 1.03
 0.58 to 1.84
 0.92

Men
 0.59
 0.39 to 0.88
 0.009
 0.74
 0.26 to 2.12
 0.58
RF negative
 All
 0.70
 0.54 to 0.90
 0.006
 1.24
 0.71 to 2.14
 0.45

Women
 0.88
 0.65 to 1.18
 0.39
 0.94
 0.47 to 1.90
 0.87

Men
 0.34
 0.20 to 0.60
 0.0001
 2.03
 0.88 to 5.29
 0.15
Anti-CCP positive
 All
 0.86
 0.70 to 1.07
 0.17
 1.01
 0.61 to 1.71
 0.98

Women
 1.02
 0.80 to 1.31
 0.88
 1.12
 0.63 to 2.00
 0.70

Men
 0.54
 0.36 to 0.83
 0.003
 0.79
 0.28 to 2.24
 0.65
Anti-CCP negative
 All
 0.69
 0.54 to 0.89
 0.004
 1.07
 0.62 to 1.84
 0.82

Women
 0.82
 0.61 to 1.10
 0.19
 0.86
 0.43 to 1.73
 0.67

Men
 0.4
 0.2 to 0.7
 0.0004
 1.8
 0.7 to 4.6
 0.26

CCP, cyclic citrullinated peptide; CI, confidence interval; OR, odds ratio; RF, rheumatoid factor.

Olsson et al. Arthritis Research & Therapy 2007 9:R98   doi:10.1186/ar2299

Open Data